Sign Out
Duodenal ulcer, Gastric ulcer, moderate and severe reflux esophagitis: The recommended intravenous dosage is one vial (40mg pantoprazole) per day.
Long-term management of Zollinger-Ellison Syndrome and other pathological hypersecretory conditions. Patients should start their treatment with a daily dose of 80mg. Thereafter, the dosage can be titrated up or down as needed using measurements of gastric acid secretion to guide. With dose above 80mg daily, the dose should be divided and given twice daily. A temporary increase of the dosage above 160mg pantoprazole is possible but should not be applied longer than required for adequate acid control. In case of rapid acid control is required a starting dose of 2x80mg pantoprazole is sufficient to manage a decrease of acid output into the target range (<10mEq/h) within one hour in the majority of patients. Transition from intravenous to oral formulations of pantoprazole should be performed as soon as it is clinically justified.
Reconstitution: A ready-to-use solution is prepared by injecting 10ml of physiological sodium chloride solution into the vial containing the dry powder. Reconstituted solution may be given intravenously (over 2 minutes) or may be added to 100ml of 0.9% sodium chloride injection or 5% glucose injection (for 15-minute infusion at a rate of approximately 7ml/min).
The admixed solution is stable up to 24 hours at 30°C.
Stripole should not be prepared or mixed with solvents other than those stated.
As soon as oral therapy is possible, treatment with pantoprazole I.V should be discontinued and 40mg oral pantoprazole should be administered instead.
The drug should be administered intravenously over 2-15 minutes.
Use in children: There are no data currently available on the use of pantoprazole in children.
Use in Elderly: Dosage adjustment not required.
Renal impairment: Dosage adjustment not required.
Hepatic impairment: Dosage adjustment not required. In patients with severe hepatic impairment the dose should be reduced to 20mg per day.
